

# **Convention on Health Analysis and Management**

## **CHAM 2015**

### **Interview with French Minister Emmanuel Macron**

*Moderators : Brice Gayet, Guy Vallancien*

#### **1. France, an open-data country**

France is an open-data country, and increasingly so. In recent years, the country has made considerable progress towards freedom of information, and will continue to do so. In other business sectors, the key questions revolve around data ownership and the potential cost of creating it. As data distribution enables economic players to innovate, we must make sure not to discourage those wanting to produce it. A balance must be found for incentivizing data production.

#### **2. The quest for faster innovation**

France should capitalize on its historical strengths to help major pharmaceutical manufacturers develop more-innovative models. In terms of clinical trials and innovative therapies, France and its industries must do more. We need to go faster and focus more on capital investment, in conditions that offer a prize for the first rival to reach the market. In this respect, France reveals some weaknesses that must be addressed. We must do everything possible to reduce timelines. If we don't, France could lose its most dynamic economic players.

#### **3. Easier access to equity to gain speed**

Project launches in the health sector require enormous amounts of money. In France, even when public stakeholders are involved, problems are encountered at the 3<sup>rd</sup> and 4<sup>th</sup> round of funding. Unlike other industries, health sector projects require more time for the innovation to reach the market, but with sufficient funds it is possible to get there faster. To do so, *a priori* controls should be shifted to *a posteriori* controls, to limit the time needed to obtain official authorizations.

#### **4. Intense development of personal health data: the end of solidarity and pooled costs?**

In a future where personal health data could be used to establish predictive scenarios for every patient, those considered to have a low risk of contracting a serious and/or degenerative disease could end up refusing to pay the same insurance premiums as their fellow man. This creates an ethical conundrum. The ethical and philosophical issues raised should be addressed without delay.